Tanvex BioPharma, Inc. (TPE:6541)
Taiwan
· Delayed Price · Currency is TWD 62.50
+1.30 (2.12%)
Apr 29, 2025, 1:30 PM CST
Tanvex BioPharma Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Cash & Equivalents | 376.96 | 380.75 | 786.23 | 2,223 | 2,069 | Upgrade
|
| Cash & Short-Term Investments | 376.96 | 380.75 | 786.23 | 2,223 | 2,069 | Upgrade
|
| Cash Growth | -1.00% | -51.57% | -64.63% | 7.46% | -14.78% | Upgrade
|
| Accounts Receivable | 0.07 | 9.4 | 0.33 | 2.52 | - | Upgrade
|
| Other Receivables | 31.58 | 27.43 | 27.36 | 25.31 | 25.57 | Upgrade
|
| Receivables | 31.65 | 36.83 | 27.69 | 27.84 | 25.57 | Upgrade
|
| Inventory | 217.84 | 108.29 | 170.84 | 90.33 | 50.08 | Upgrade
|
| Prepaid Expenses | 49.18 | 78.35 | 58.95 | 60.85 | 119.25 | Upgrade
|
| Total Current Assets | 675.62 | 604.21 | 1,044 | 2,402 | 2,264 | Upgrade
|
| Property, Plant & Equipment | 1,827 | 1,928 | 2,151 | 2,114 | 1,906 | Upgrade
|
| Other Intangible Assets | 7.07 | 3.38 | 12.07 | 10.17 | 11.96 | Upgrade
|
| Other Long-Term Assets | 225.3 | 227.67 | 213.47 | 187.58 | 190.98 | Upgrade
|
| Total Assets | 2,735 | 2,763 | 3,420 | 4,714 | 4,373 | Upgrade
|
| Accrued Expenses | 134.27 | - | 115.93 | 137.49 | 210.99 | Upgrade
|
| Current Portion of Long-Term Debt | - | - | - | - | 54.77 | Upgrade
|
| Current Portion of Leases | 160.01 | 163.45 | 124.65 | 88.75 | 65.74 | Upgrade
|
| Current Unearned Revenue | 11.11 | 6.91 | 28.07 | - | - | Upgrade
|
| Other Current Liabilities | 42.75 | 193.38 | 34.63 | 22.28 | 21.6 | Upgrade
|
| Total Current Liabilities | 348.14 | 363.73 | 303.29 | 248.51 | 353.1 | Upgrade
|
| Long-Term Debt | - | - | - | - | 35.53 | Upgrade
|
| Long-Term Leases | 1,488 | 1,568 | 1,715 | 1,670 | 1,363 | Upgrade
|
| Long-Term Unearned Revenue | 5.47 | 10.23 | - | - | - | Upgrade
|
| Other Long-Term Liabilities | - | - | 10.47 | - | - | Upgrade
|
| Total Liabilities | 1,842 | 1,942 | 2,028 | 1,919 | 1,752 | Upgrade
|
| Common Stock | 1,641 | 1,340 | 3,527 | 3,525 | 3,116 | Upgrade
|
| Additional Paid-In Capital | 13,567 | 12,431 | 11,061 | 10,988 | 9,653 | Upgrade
|
| Retained Earnings | -14,136 | -12,755 | -12,969 | -11,327 | -9,784 | Upgrade
|
| Comprehensive Income & Other | -177.94 | -194.17 | -227.09 | -390.12 | -364.04 | Upgrade
|
| Shareholders' Equity | 893.31 | 821.11 | 1,391 | 2,795 | 2,621 | Upgrade
|
| Total Liabilities & Equity | 2,735 | 2,763 | 3,420 | 4,714 | 4,373 | Upgrade
|
| Total Debt | 1,648 | 1,732 | 1,839 | 1,759 | 1,519 | Upgrade
|
| Net Cash (Debt) | -1,271 | -1,351 | -1,053 | 463.95 | 549.19 | Upgrade
|
| Net Cash Growth | - | - | - | -15.52% | -73.66% | Upgrade
|
| Net Cash Per Share | -8.19 | -10.48 | -8.95 | 4.27 | 6.14 | Upgrade
|
| Filing Date Shares Outstanding | 164.07 | 133.96 | 117.64 | 117.57 | 103.95 | Upgrade
|
| Total Common Shares Outstanding | 164.07 | 133.96 | 117.64 | 117.57 | 103.95 | Upgrade
|
| Working Capital | 327.48 | 240.48 | 740.43 | 2,153 | 1,910 | Upgrade
|
| Book Value Per Share | 5.44 | 6.13 | 11.83 | 23.77 | 25.21 | Upgrade
|
| Tangible Book Value | 886.24 | 817.73 | 1,379 | 2,785 | 2,609 | Upgrade
|
| Tangible Book Value Per Share | 5.40 | 6.10 | 11.73 | 23.68 | 25.10 | Upgrade
|
| Machinery | 1,089 | 982.54 | 975.18 | 889.53 | 884.87 | Upgrade
|
| Construction In Progress | 44.34 | 83.71 | 72.82 | 53.8 | 48.78 | Upgrade
|
| Leasehold Improvements | 509.94 | 415.69 | 388.62 | 318.95 | 322.42 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.